Current Herpes Treatment Guidelines: What Really Works Now
- 01. Current standard of care for herpes treatment
- 02. Mainstay herpes medications and dosing
- 03. Suppressive therapy recommendations
- 04. Changes: what's new in 2024-2026 guidelines
- 05. Table: Typical herpes treatment regimens by scenario (2024-2026)
- 06. Adjunctive and supportive care measures
- 07. Special populations: pregnancy, HIV, and immunocompromised
- 08. Guideline-driven behavioral and prevention strategies
- 09. What are the current first-line drugs for herpes?
Current standard of care for herpes treatment
Current herpes treatment guidelines, as updated in 2024 by major dermatology and infectious-disease groups such as the European Dermatology Forum and the U.S. CDC, center on three pillars: early antiviral therapy for primary outbreaks, episodic treatment for recurrent episodes, and suppressive therapy for people with frequent or severe recurrences. Oral nucleoside analogs-acyclovir, valacyclovir, and famciclovir-remain first-line, with intravenous acyclovir reserved for serious or disseminated disease, especially in immunocompromised patients.
For genital herpes, the 2024 European guidelines emphasize that treatment should start as soon as symptoms appear or at the first prodrome (tingling, burning, itching) to reduce lesion duration by about 1-2 days and to lower viral shedding and contagiousness. Suppressive therapy is now recommended more consistently for patients with 6-10 or more recurrences per year, a threshold derived from randomized trials showing roughly 70-80% reduction in outbreak frequency when taken daily.
Mainstay herpes medications and dosing
The "workhorse" drugs across recent guidelines are still the same three oral antivirals, but with refined dosing and clearer indications for each scenario. For primary genital herpes in an immunocompetent adult, typical regimens include acyclovir 400 mg three times daily for 7-10 days, valacyclovir 500 mg twice daily for 7-10 days, or famciclovir 250 mg twice daily for 7-10 days. Intravenous acyclovir is added for patients with extensive disease, systemic symptoms, or inability to swallow.
For episodic treatment of recurrent genital or labial herpes, guidelines favor short, high-dose "kick-start" regimens such as valacyclovir 2 g by mouth twice daily for 1 day, or famciclovir 1 g twice over 12 hours. These 1-day courses are now considered as effective as 5-day courses for many patients, which improves adherence and reduces pill burden.
Suppressive therapy recommendations
Long-term suppressive therapy is no longer reserved only for the most severe cases; 2024 European and CDC-aligned guidance explicitly recommends daily antivirals for anyone with six or more recurrences per year, or for those whose outbreaks cause significant psychosocial distress or functional impairment. Common regimens include valacyclovir 500 mg daily, acyclovir 400 mg twice daily, or famciclovir 250 mg twice daily.
Trial data cited in the 2024 European guidelines show that suppressive valacyclovir reduces annual outbreak counts from a median of 10-12 to 2-3 per year in HSV-2 genital herpes, and cuts transmission to uninfected partners by about 40-50% when combined with condoms. Most guidelines now suggest that suppression can be paused after 6-12 months to reassess the natural history; isolated recurrences after stopping do not automatically require restarting therapy.
Changes: what's new in 2024-2026 guidelines
The 2024 European and aligned national guidelines introduced several subtle but clinically important shifts in thinking about herpes management. These include a stronger push for early diagnosis (including serology in selected cases), routine discussion of sexual-health counseling and partner notification, and explicit guidance on herpes in pregnancy and among people living with HIV.
One key update is tighter coordination between obstetrics and STI guidelines on genital herpes in pregnancy: daily antiviral suppression from 36 weeks reduces the risk of detectable genital shedding at delivery and may allow more women to avoid cesarean section if lesions are absent and viral titers are low. The new documents also emphasize that antiviral doses for people living with HIV should follow the same schedules as for others unless they are moderately to severely immunosuppressed, in which case doses may be doubled.
Table: Typical herpes treatment regimens by scenario (2024-2026)
| Scenario | Drug | Dose and schedule | Notes |
|---|---|---|---|
| Primary genital herpes | Acyclovir | 400 mg PO three times daily for 7-10 days | First-line for immunocompetent adults; start early. |
| Primary genital herpes | Valacyclovir | 500 mg PO twice daily for 7-10 days | Better bioavailability; preferred for convenience. |
| Recurrent episode (episodic) | Valacyclovir | 2 g PO twice over 12 hours (1-day course) | Equal efficacy to 5-day courses; high adherence. |
| Frequent recurrences (suppressive) | Valacyclovir | 500 mg PO daily | For ≥6 recurrences/year; cuts transmission by ~40-50%. |
| Severe systemic or immunocompromised disease | Acyclovir IV | 5-10 mg/kg every 8 hours | Adjust for renal function; duration ≥7 days or until healing. |
Adjunctive and supportive care measures
Guidelines now explicitly endorse several supportive measures alongside antivirals to reduce pain and speed healing. These include topical lidocaine 2-5% gel or cream for local analgesia, sitz baths, loose cotton underwear, and over-the-counter pain relief such as acetaminophen or NSAIDs. Counselors and clinicians are advised to address psychosocial distress with brief counseling, accurate risk-communication, and referral for anxiety or depression when needed.
Topical antiviral creams (e.g., acyclovir cream) are no longer recommended as primary therapy because they only modestly reduce lesion duration and do not meaningfully lower transmission. Similarly, topical antibiotics are discouraged unless there is clear secondary bacterial infection, to avoid local sensitization and antibiotic overuse.
Special populations: pregnancy, HIV, and immunocompromised
In pregnant women with recurrent genital herpes, guidelines strongly recommend initiating daily suppressive therapy (typically valacyclovir 500 mg once daily) from 36 weeks until delivery to reduce viral shedding and clinical lesions at birth. This approach has been associated with a roughly 70% reduction in lesions at delivery compared with no suppression, and may allow a vaginal birth in selected cases.
For people living with HIV who have normalized CD4 counts on antiretroviral therapy, standard herpes dosing is advised, but those with moderate to severe immunosuppression may require twice the usual oral dose or longer courses. Non-healing lesions in this group often prompt virologic testing and sometimes intravenous acyclovir or foscarnet for resistant strains.
Guideline-driven behavioral and prevention strategies
Modern guidelines treat herpes not just as a medical condition but as a sexual-health and behavioral-medicine issue. They recommend that all patients receive structured counseling on disclosure to partners, use of condoms or dental dams, and avoidance of sexual contact during prodromes or active lesions, which can reduce transmission risk by about 30-40% even without antivirals.
Many guidelines now incorporate a brief "serious but not rare" communication framework: they stress that genital herpes is common (an estimated 13% of adults globally have HSV-2, and many more HSV-1 genital infections), usually self-limited, and manageable, while still acknowledging real pain and stigma. This framing aims to reduce shame and improve adherence to antiviral and behavioral strategies.
What are the current first-line drugs for herpes?
The current first-line drugs for herpes simplex virus infections are still acyclovir, valacyclovir, and famciclovir, all taken orally for most uncomplicated cases. Valacyclovir is often preferred for genital herpes because of its higher bioavailability and once- or twice-daily dosing, which improves adherence.
Key concerns and solutions for Current Herpes Treatment Guidelines What Really Works Now
How have herpes treatment guidelines changed recently?
Recent 2024 European and CDC-aligned guidelines place greater emphasis on early antiviral initiation, routine suppressive therapy for frequent recurrences, and integrated counseling on sexual health and partner communication. They also tighten recommendations for herpes in pregnancy and among people living with HIV, including earlier use of antivirals and clearer criteria for cesarean section.
When should suppressive therapy be started?
Suppressive therapy is recommended for patients with six or more genital herpes recurrences per year, or for those whose outbreaks cause significant pain, functional limitation, or psychosocial distress. Most guidelines suggest starting with daily valacyclovir 500 mg, with reassessment after 6-12 months to see whether the virus remains well-controlled.
Can herpes be cured with current guidelines?
No current guideline-aligned regimen can cure herpes; the virus establishes lifelong latency in sensory ganglia and may reactivate despite antiviral therapy. However, modern treatments can significantly reduce the frequency and severity of outbreaks and lower transmission risk, turning herpes into a manageable chronic condition for many patients.
Is topical herpes cream still recommended?
Topical herpes creams, such as acyclovir cream, are no longer recommended as primary therapy in updated guidelines because they only modestly shorten lesion duration and do not reduce viral shedding or transmission. They may occasionally be used as an adjunct for localized pain relief, but oral antivirals remain the standard of care.
Are there new drugs or vaccines on the horizon?
Guideline documents note that traditional nucleoside analogs have limitations, including variable efficacy and emerging resistance in immunocompromised hosts, which has spurred development of helicase-primase inhibitors and other novel agents. Several candidate vaccines and gene-therapy approaches are in early or mid-stage trials, but none are yet incorporated into "current" herpes treatment guidelines.
How long should a primary herpes episode be treated?
For a primary genital herpes episode in an immunocompetent patient, most guidelines recommend 7-10 days of oral antivirals (e.g., acyclovir 400 mg three times daily or valacyclovir 500 mg twice daily). Treatment should ideally start within 48 hours of symptom onset, but benefit can still occur even when started later in the course.
Should partners be treated or tested?
Current guidelines do not recommend treating asymptomatic partners with antivirals as a standard policy, but they encourage thorough sexual-health counseling and partner testing if symptoms or risk factors arise. Partners may benefit from learning about HSV serology, condom use, and avoiding contact during outbreaks to reduce transmission risk.